The Great Healthcare Debate 7 DAYS · Free panel + drinks · 12 May · London RSVP free →

Hoechst South Africa Growth Up On Forecast

31 March 1996

Announcing the first year-end financial results since listing on the Johannesburg, South Africa, Stock Exchange last July (Marketletters passim), Hoechst South Africa Ltd produced 1995 attributable earnings of 60.5 million rand ($15.4 million). This is significantly higher than the prospectus' forecast of 57.7 million, thus maintaining its consistent pattern of growth of the past six years. Net operating income (including income from associated companies on a pretax basis) for the year increased 32% to 115.9 million rand.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight